First CAPS drugs recommended for EU approval
24 July 2009
Katie McQue
Please Login to read the full article.
24 July 2009
Katie McQue
The CHMP has endorsed the EU approval of two rival potential therapies for cryopyrin-associated periodic syndromes (CAPS) – Novartis's fully humanised monoclonal antibody Ilaris (canakinumab) and Regeneron's Arcalyst (rilonacept).
Should these products gain approval, as...
Please Login to read the full article.
RELATED CONTENT
NEWS
- Panel urges FDA to reject Novartis gouty arthritis drug on safety concerns
- US FDA to seek panel's advice on 'complicated' matters with Novartis gouty arthritis drug
- FDA acceptance of Arcalyst sBLA puts Regeneron closer to gout market
- Regeneron leaps on positive FDA review of wet AMD drug
EVENTS
Today
London
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
JOB OF THE WEEK
Promote your vacancy here
